PX-12

Catalog No.S7947 Synonyms: DB05448, 1-methyl propyl 2-imidazolyl disulfide

For research use only.

PX-12 (DB05448, 1-methyl propyl 2-imidazolyl disulfide) is a potent thioredoxin-1 (Trx-1) inhibitor by irreversibly thioalkylation of Cys73 of Trx-1. Phase 2.

PX-12 Chemical Structure

CAS No. 141400-58-0

Selleck's PX-12 has been cited by 6 Publications

Purity & Quality Control

Choose Selective Thioredoxin Inhibitors

Biological Activity

Description PX-12 (DB05448, 1-methyl propyl 2-imidazolyl disulfide) is a potent thioredoxin-1 (Trx-1) inhibitor by irreversibly thioalkylation of Cys73 of Trx-1. Phase 2.
Targets
Trx-1 [1]
()
In vitro

In MCF-7 and HT-29 cells, PX-12 prevents the hypoxia (1% oxygen)-induced increase in HIF-1alpha protein, and decreases HIF-1-trans-activating activity, VEGF formation, and inducible nitric oxide synthase. PX-12 also inhibits the growth of MCF-7 and HT-29 cells with IC50s of 1.9 μM and 2.9μM, respectively. [1] PX-12 also inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase. [2] In A549 cells, PX-12 inhibits cell growth via G2/M phase arrest, and Bax-mediated and ROS-dependent apoptosis. [3] In hepatocelluar carcinoma cells, PX-12 exerts a synergistic effect with 5-FU to significantly suppress tumorigenicity. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T84 M{LXemZ2dmO2aX;uJIF{e2G7 MnezN{BpenN? NXPjTJo4UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDD0bIlwemWmb4jpck1u\WSrYYTl[EBVTzJiYXP0bZZifGmxbjDlfJBz\XO|ZXSgbY4hXDh2IHPlcIx{KGG|c3Xzd4VlKGG|IHLsc4Ns[WSnIH;mJFUu[mmxdHnuZY1q\G:yZX70fYxidWmwZTDpcoNwenCxcnH0bY9vKGGodHXyJFMhcHK|IHL5JIZtfW:{ZYPj[Y5k\SCvaXPyc5Nkd3CrYzDhcoFtgXOrczygTWM2OD1{LkGx{txO M4TzcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{K3OlU3Lz5{M{OyO|Y2PjxxYU6=
MEF Mnr0R5l1d3SxeHnjbZR6KGG|c3H5 MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDNSWYh[2WubIOsJGxFPTB;Mj63{txO M1zjW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUK4PFc3Lz5{MkGyPFg4PjxxYU6=
Ramos MmnUR5l1d3SxeHnjbZR6KGG|c3H5 NEnlXmo4OiCqcoO= NX72UHl3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmGvb4OgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiTFS1NF0{NjUQvF2= NWD2UWkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNlg5PzZpPkKyNVI5QDd4PD;hQi=>
PancO2 NE\HdWREgXSxdH;4bYNqfHliYYPzZZk> NXPSUoM{PzJiaILz MnvCR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgVIFv[09{IHPlcIx{KGGodHXyJFczKGi{czDifUBkenm|dHHsJJZqd2yndDDzeIFqdmmwZzygUGQ2OD1|LkpOwG0> Mkm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMki4O|YoRjJ{MUK4PFc3RC:jPh?=
T24 NWPwdIp5S3m2b4TvfIlkcXS7IHHzd4F6 M{XKU|czKGi{cx?= NWXhUGUxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDJ2IHPlcIx{KGGodHXyJFczKGi{czDifUBkenm|dHHsJJZqd2yndDDzeIFqdmmwZzygUGQ2OD12LkdOwG0> MlT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMki4O|YoRjJ{MUK4PFc3RC:jPh?=
B78 M4K0[GN6fG:2b4jpZ4l1gSCjc4PhfS=> MVO3NkBpenN? NULy[XVGS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSjd6IHPlcIx{KGGodHXyJFczKGi{czDifUBkenm|dHHsJJZqd2yndDDzeIFqdmmwZzygUGQ2OD13zszN NVq3dHhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNlg5PzZpPkKyNVI5QDd4PD;hQi=>
CT26 NUn2WmFMS3m2b4TvfIlkcXS7IHHzd4F6 MVG3NkBpenN? Ml;zR5l1d3SxeHnjbZR6KGGpYXnud5Qhf2muZDD0fZBmKG2xdYPlJGNVOjZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDMSFUxRTVwMt88US=> NHTVdHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
K562 M3zkZWN6fG:2b4jpZ4l1gSCjc4PhfS=> MVO3NkBpenN? NWrYSoxYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCOREWwQVUvPc7:TR?= NYLhOG9IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNlg5PzZpPkKyNVI5QDd4PD;hQi=>
M21 MVXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHrmPYhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF2yNUBk\WyuczygS2k2OD16LkROwG0> NIjqXVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEWwNlY{QSd-MUi1NFI3Ozl:L3G+
MCF7 NH3xPVdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M4TnZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczygS2k2OD16LkROwG0> M1vUd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUCyOlM6Lz5zOEWwNlY{QTxxYU6=
MCF7 NIfzPIZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NV3nPJNlPDhiaILz MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIhdWW2aH;kMEBIUTVyPUiuN:69VQ>? NEDURlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[xO|QyPCd-MUi2NVc1OTR:L3G+
M21 MmXZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Ml\SOFghcHK| MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE1{MTDj[YxteyCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBu\XSqb3SsJGdKPTB;OD6z{txO NUPyemV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2NVc1OTRpPkG4OlE4PDF2PD;hQi=>
Raji M2i3WWN6fG:2b4jpZ4l1gSCjc4PhfS=> NVzxcHpMPzJiaILz NFXDc2FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT[WqrIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEyGNUC9PE45|ryP NHz4bpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
EMT6 M3zUR2N6fG:2b4jpZ4l1gSCjc4PhfS=> MmLtO|IhcHK| MnvkR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgSW1VPiClZXzsd{Bi\nSncjC3NkBpenNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFzEOVA:OTFwNt88US=> NFzrTnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
HT29 NUDFU5VTSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMkmgZ4VtdHNuIFfJOVA:OjYQvF2= M2jDO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUCyOlM6Lz5zOEWwNlY{QTxxYU6=
HT29 MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHT2XFA1QCCqcoO= MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMkmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIhdWW2aH;kMEBIUTVyPUK1{txO NFHvXIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[xO|QyPCd-MUi2NVc1OTR:L3G+
M21 M{C1cWZ2dmO2aX;uJIF{e2G7 MYiyOUBvVQ>? NF23cJMyPiCqcoO= M4DvcnN1cW23bHH0bY9vKG:oIH71Z4xm[XJidILhcpNtd2OjdHnvckBw\iC2aHnvdoVld3irbj2xJIZzd21iY4n0c5NwdCCrbjDoeY1idiCPMkGgZ4VtdHNiYYSgNlUhdk1iYX\0[ZIhOTZiaILzJIJ6KGmvbYXuc4N6fG:obIXvdoV{[2WwY3W= NF\VdoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[xO|QyPCd-MUi2NVc1OTR:L3G+
Raji NFzaVY1HfW6ldHnvckBie3OjeR?= MoLBOUB1dyBzMDD1US=> NFLWWok1KHSxIEK0JIhzew>? M{XDUmlv\HWldHnvckBw\iCWcoigcXJPSSCneIDy[ZN{cW:wIHnuJIh2dWGwIGLhbokh[2WubIOgZZQhPSC2bzCxNEB2VSCjZoTldkA1KHSxIEK0JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN? M4rIeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUK4PFc3Lz5{MkGyPFg4PjxxYU6=
Raji MUHGeY5kfGmxbjDhd5NigQ>? M4TIRVExKHSxIEKwJJVO NHfQVmI1KHSxIEigbJJ{ NW\sXmdLUW6mdXP0bY9vKG:oIGTyfEBxem:2ZXnuJIV5eHKnc4Ppc44hcW5iaIXtZY4hWmGsaTDj[YxteyCjdDCxNEB1dyB{MDD1UUBi\nSncjC0JJRwKDhiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= M37QelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUK4PFc3Lz5{MkGyPFg4PjxxYU6=
DAOY NVrqWXVkeUiWUzDhd5NigQ>? M3HIU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| NUPXSYVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 MWrxTHRUKGG|c3H5 M1nZbZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz M3zGdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NV\GcmdMeUiWUzDhd5NigQ>? NV3uUVZNeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC Mn3KdWhVWyCjc4PhfS=> MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NGmxSXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 M1TzepFJXFNiYYPzZZk> M17tcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 MXrxTHRUKGG|c3H5 NF;6d4NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 MUnxTHRUKGG|c3H5 NEP4SYxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= MnjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 MkfCdWhVWyCjc4PhfS=> MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| M2S1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NWj5d3l3eUiWUzDhd5NigQ>? MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> NHTqTmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) M4e0RZFJXFNiYYPzZZk> MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NXSzenF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 NYDyVWN4eUiWUzDhd5NigQ>? NYDyfZJEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| NEnUb3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC M2rQPJFJXFNiYYPzZZk> NFrPfFByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy| NEfJcWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 MWjxTHRUKGG|c3H5 MlrzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOTJiY3XscJM> MnLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 MVTxTHRUKGG|c3H5 MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDMRW4uPSClZXzsdy=> M2nWZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32 MV7xTHRUKGG|c3H5 NHjjNnlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{ MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) MnXUdWhVWyCjc4PhfS=> NV;5S2lyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NVLPSHpGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NV;mbFVUeUiWUzDhd5NigQ>? NEHUNGlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{ M3fodlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MVfxTHRUKGG|c3H5 NGXwdm9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy| M1jCc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
In vivo In mice bearing MCF-7 tumor xenografts, PX-12 (12 mg/kg, i.p.) decreases HIF-1α and VEGF protein levels and microvessel density. [1]

Protocol (from reference)

Cell Research:[1]
  • Cell lines: MCF-7 and HT-29 cells
  • Concentrations: ~10 μM
  • Incubation Time: 72 h
  • Method: Cell growth is measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cells are exposed to a range of concentrations of PX-12 or pleurotin for 16 h in air or hypoxia (1% oxygen). The cells are then washed with warm drug-free medium and grown in air for the remainder of the 72-h incubation.
  • (Only for Reference)
Animal Research:[1]
  • Animal Models: Mice bearing MCF-7 tumor xenografts
  • Dosages: 12 mg/kg
  • Administration: i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 38 mg/mL
(201.79 mM)
Water Insoluble
Ethanol '38 mg/mL

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 188.31
Formula

C7H12N2S2

CAS No. 141400-58-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC(C)SSC1=NC=CN1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00736372 Completed Drug: PX-12 Metastatic Cancer|Advanced Cancer Cascadian Therapeutics Inc.|Seagen Inc. June 2008 Phase 1
NCT00417287 Terminated Drug: PX-12 Pancreatic Neoplasms Cascadian Therapeutics Inc.|National Cancer Institute (NCI)|Translational Genomics Research Institute|Seagen Inc. December 2006 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy PX-12 | PX-12 supplier | purchase PX-12 | PX-12 cost | PX-12 manufacturer | order PX-12 | PX-12 distributor